Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Rocket Pharmaceuticals (RCKT) Leases (2018 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Leases for 8 consecutive years, with $40.2 million as the latest value for Q4 2025.

  • Quarterly Leases rose 863.55% to $40.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40.2 million through Dec 2025, up 863.55% year-over-year, with the annual reading at $40.2 million for FY2025, 863.55% up from the prior year.
  • Leases hit $40.2 million in Q4 2025 for Rocket Pharmaceuticals, down from $40.7 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $49.5 million in Q2 2021 to a low of $200000.0 in Q1 2023.
  • Historically, Leases has averaged $25.7 million across 5 years, with a median of $40.5 million in 2025.
  • Biggest five-year swings in Leases: tumbled 99.58% in 2023 and later soared 21889.5% in 2024.
  • Year by year, Leases stood at $1.6 million in 2021, then surged by 2874.12% to $46.7 million in 2022, then fell by 4.6% to $44.5 million in 2023, then crashed by 90.63% to $4.2 million in 2024, then surged by 863.55% to $40.2 million in 2025.
  • Business Quant data shows Leases for RCKT at $40.2 million in Q4 2025, $40.7 million in Q3 2025, and $3.8 million in Q2 2025.